Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

Chronic myelomonocytic leukemia: JAK2 inhibitor ruxolitinib has promising efficacy

Science Daily - 28 May 2015 20:52
Scientists are reporting on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients.
Full Article at Science Daily

More Science News
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard